# Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

> **NCT04459065** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Saskatchewan** · enrollment: 36 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** IRDye800CW-nimotuzumab

## Key facts

- **NCT ID:** NCT04459065
- **Lead sponsor:** University of Saskatchewan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459065, "Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04459065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*